DADC
SPRO icon

D.A. Davidson & Co’s Spero Therapeutics SPRO Stock Holding History

D.A. Davidson & Co’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,800
Closed -$8K – 1348
2022
Q2 		$8K Sell
10,800
-33,000
-75% -$96K ﹤0.01% 1271
2022
Q1 		$381K Hold
43,800
– – ﹤0.01% 983
2021
Q4 		$701K Buy
43,800
+800
+2% +$12.7K 0.01% 764
2021
Q3 		$792K Buy
43,000
+9,000
+26% +$144K 0.01% 699
2021
Q2 		$475K Buy
34,000
+500
+1% +$6.99K 0.01% 850
2021
Q1 		$493K Buy
33,500
+3,500
+12% +$61.6K 0.01% 812
2020
Q4 		$582K Buy
30,000
+500
+2% +$7.79K 0.01% 656
2020
Q3 		$329K Buy
29,500
+7,700
+35% +$91.1K 0.01% 748
2020
Q2 		$295K Buy
21,800
+6,800
+45% +$76.3K 0.01% 756
2020
Q1 		$121K Hold
15,000
– – ﹤0.01% 919
2019
Q4 		$144K Buy
15,000
+3,000
+25% +$32.4K ﹤0.01% 973
2019
Q3 		$127K Buy
12,000
+2,000
+20% +$21.1K ﹤0.01% 947
2019
Q2 		$115K Buy
+10,000
New +$120K ﹤0.01% 947

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

D.A. Davidson & Co's SPRO Position: Q3 2022 in Review

D.A. Davidson & Co sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 10,800 shares — an estimated $8K sold.

D.A. Davidson & Co first reported a position in SPRO in Q2 2019 and held it in 13 quarters. The position peaked at $792K in Q3 2021. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • D.A. Davidson & Co reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.A. Davidson & Co sold 10,800 Spero Therapeutics shares in Q3 2022, an estimated $8K.
  • D.A. Davidson & Co first reported a position in Spero Therapeutics in Q2 2019 and held it in 13 quarters.
  • D.A. Davidson & Co's Spero Therapeutics position peaked at $792K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on D.A. Davidson & Co's 13F filing for Q3 2022, filed 7 Nov 2022.